feedback

Course Director

John B. Buse, MD, PhD
John B. Buse, MD, PhD

NC Translational and Clinical Sciences Institute
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Faculty

David Cherney
David Cherney, MD, PhD, FRCP(C)

University of Toronto
University Health Network
Toronto, Ontario, Canada

Mikhail Kosiborod
Mikhail Kosiborod, MD, FACC, FAHA

Saint Luke’s Health System
Haverty Cardiometabolic Center of Excellence
Cardiometabolic Research Program, Saint Luke’s Mid America Heart Institute
University of Missouri Kansas City, Missouri

Accredited by

Penn State College of Medicine

View Activity Materials

Activity Description and Educational Objectives

Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD.

Upon completion of this activity, participants should be able to:
  • Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines
  • Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM
  • Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM
  • Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases

Target Audience

This activity has been designed to meet the educational needs of endocrinologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the management of comorbid cardiometabolic diseases.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 23, 2020 - July 22, 2021
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair
John B. Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, NC Translational and Clinical Sciences Institute
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina

John B. Buse, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Adocia; AstraZeneca; Cirius Therapeutics; CSL Behring; Dance Biopharm Inc.; Eli Lilly and Company; MannKind Corporation; Mellitus Health, Inc.; Neurimmune; NovaTarg Therapeutics; Novo Nordisk, Inc.; Pendulum Therapeutics, Inc.; Senseonics; Stability Health; VTV Therapeutics; and Zafgen, Inc.
Grant/Research Support from National Institutes of Health (NIH); Novo Nordisk, Inc.; Patient-Centered Outcomes Research Institute (PCORI); sanofi-aventis U.S. LLC; Tolerion, Inc.; and VTV Therapeutics.

Faculty
David Cherney, MD, PhD, FRCP(C)
Associate Professor of Medicine
University of Toronto
Clinician Scientist
Division of Nephrology
University Health Network
Toronto, Ontario, Canada

David Cherney, MD, PhD, FRCP(C), has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Corporation; AstraZeneca; Bayer Inc.; Boehringer Ingelheim (Canada) Ltd.; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Inc.; Merck & Co., Inc.; Mitsubishi Tanabe Pharma Canada; Novo Nordisk Canada Inc.; ProMetic Life Sciences Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Boehringer Ingelheim (Canada) Ltd.; Eli Lilly and Company; Janssen Inc.; Merck & Co., Inc.; Novo Nordisk Canada Inc.; and Sanofi.

Mikhail Kosiborod, MD, FACC, FAHA
Vice President for Research, Saint Luke’s Health System
Co-Director, Haverty Cardiometabolic Center of Excellence
Director, Cardiometabolic Research Program, Saint Luke’s Mid America Heart Institute
Professor of Medicine, University of Missouri
Kansas City, Missouri

Mikhail Kosiborod, MD, FACC, FAHA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amarin Corporation plc; Amgen Inc.; Applied Therapeutics; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline; Glytec, LLC; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk, Inc.; sanofi-aventis U.S. LLC; and Vifor Pharma Management Ltd.
Grant/Research Support from AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc.

Medical Directors
Angela McIntosh
PVI, PeerView Institute for Medical Education

Angela McIntosh has no financial interests/relationships or affiliations in relation to this activity.

Margery Tamas
PVI, PeerView Institute for Medical Education

Margery Tamas has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6602-21-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca LP.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.